en · de · es · fr · pt
ipamorelin-notes.peptides6823.com › Faq › Receptor Selectivity And Secretagogue Signaling — Questions and Answers

Receptor Selectivity And Secretagogue Signaling — Questions and Answers

By Editorial Desk · published 2026-05-15 · last reviewed 2026-06-04 · Faq

Everything below concerns somatotroph. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.

Last reviewed on 2026-06-04. Where a claim depends on a specific study, the study is described rather than over-claimed.

Receptor Selectivity and Secretagogue Signaling

Structural features distinguish the molecule from earlier secretagogues. An alpha-aminoisobutyric acid residue near the N-terminus and a D-naphthylalanine substitution increase receptor affinity, while C-terminal amidation improves resistance to exopeptidases. These modifications are associated with reduced stimulation of appetite and of the hypothalamic-pituitary-adrenal axis compared with hexarelin or growth hormone releasing peptide-6. Whether the same profile applies at every dose level studied is a matter of ongoing investigation rather than settled consensus.

Ipamorelin is a synthetic pentapeptide that acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. Its sequence incorporates non-natural residues, which slows enzymatic breakdown relative to short native peptides. In laboratory and early clinical work the compound is described as a selective growth hormone secretagogue because it raises growth hormone with comparatively little effect on other pituitary outputs. The degree to which that selectivity holds across species and dosing regimens remains an open question in the published literature.

Receptor Mechanism and Secretagogue Action

One distinguishing feature reported in animal studies is selectivity. Ipamorelin stimulated growth hormone release with limited elevation of adrenocorticotropic hormone or cortisol compared with earlier secretagogues such as GHRP-6. This pattern has been described as more selective for the growth hormone axis. The finding comes mainly from preclinical work, and the degree to which it holds across species and doses is not fully settled. Reports also describe effects on gastric motility in animal models, suggesting activity outside the pituitary, though the clinical relevance of this observation is uncertain.

Ipamorelin is a synthetic pentapeptide that acts on the growth hormone secretagogue receptor, also known as the ghrelin receptor. Its sequence contains five amino acid residues, including a non-natural residue that increases stability against enzymatic breakdown. The compound was developed in the 1990s as part of research into small peptides that stimulate pituitary hormone release. Unlike larger protein hormones, it can be produced by solid-phase peptide synthesis and characterized by standard analytical methods.

At the receptor level, ipamorelin binds GHS-R1a and triggers signaling through Gq-coupled pathways. Activation leads to calcium release and downstream effects in pituitary somatotroph cells. These events promote the release of growth hormone into circulation. The response depends on the presence of the receptor and on the physiological state of the animal or tissue studied. Because the receptor is also found in other tissues, effects beyond the pituitary have been examined in laboratory models, though the extent of those effects remains an area of ongoing study.

Ipamorelin at a glance

PropertyValueNotes
Molecular formulaC38H49N9O5Reported for the free peptide
Molecular mass711.85 DaMonoisotopic value
Residue motifAib-His-D-2-Nal-D-Phe-Lys-NH2Non-natural residues at positions one and three
Primary targetGHSR-1aGhrelin receptor, G protein coupled
Reported plasma half-lifeAbout two hoursValues vary with assay and subject group

Background and Receptor Selectivity

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class. It acts as an agonist at the ghrelin receptor, also called the growth hormone secretagogue receptor type 1a. The compound was designed in the 1990s during a search for agents that release growth hormone with fewer off-target hormonal effects than earlier secretagogues. It appears in the research literature under several sequence-based names. Material supplied for laboratory work is normally a lyophilized solid, and it is not marketed as an approved therapeutic in major jurisdictions.

The molecule contains five residues, including alpha-aminoisobutyric acid, D-2-naphthylalanine, and D-phenylalanine, and it ends in a lysine amide. Non-natural and D-configured residues make the chain less susceptible to common peptidases, which helps explain its resistance to rapid breakdown. Its molecular formula is C38H49N9O5, corresponding to a free-base mass near 711.9 daltons. The C-terminal amide removes a negative charge and is a recurring feature in receptor-active peptides of this family. These structural choices are usually discussed as the basis for its selectivity profile.

Published animal and early human work describes growth hormone release that is separated from comparable rises in adrenocorticotropic hormone and cortisol. Prolactin changes are reported as small in the same studies. Selectivity is attributed to binding at the ghrelin receptor and to the downstream signaling that follows, rather than to differences in how quickly the peptide is cleared. Authors commonly label the compound selective rather than potent, because the same mass produces a smaller growth hormone response than some older secretagogues tested in parallel. Whether that profile holds across species and routes of administration remains an open question.

Related pages on this site

Ipamorelin Background and Receptor Pharmacology

In animal and early human studies, ipamorelin produces pulsatile growth hormone release and a secondary rise in insulin-like growth factor 1. The magnitude and duration of that rise depend on route, sampling schedule, and the baseline endocrine state of the subject. Whether repeated exposure alters the response over time is not firmly settled, since some reports describe stable pulsatility while others note attenuation. Most published data come from small samples, which limits the strength of any general claim about long-term behavior.

Ipamorelin is a synthetic pentapeptide that belongs to the growth hormone secretagogue class of compounds. Its sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2, a structure that differs from natural ghrelin in length and in the presence of non-natural amino acid residues. Early laboratory work described it as a comparatively selective agent that stimulates growth hormone release with limited effect on other pituitary hormones. The compound is supplied as a lyophilized solid for research use and has no identified natural source in the body.

Background And Receptor Mechanism

At the molecular level, ipamorelin acts as an agonist at the growth hormone secretagogue receptor, also called the ghrelin receptor or GHS-R1a. Binding to this receptor on pituitary somatotroph cells triggers a signaling cascade that leads to growth hormone release. The effect is mediated through phospholipase C and calcium mobilization rather than through the cyclic AMP pathway used by growth hormone releasing hormone. The two pathways are complementary, and combined stimulation produces a larger response than either alone.

Compared with other secretagogues such as GHRP-2, GHRP-6, and hexarelin, ipamorelin is described as more selective. Published animal work reports little or no increase in adrenocorticotropic hormone, cortisol, or prolactin at doses that release growth hormone. This selectivity is the property most often cited in the research literature. Whether the same profile holds across species and dosing schedules remains an open question, since human data are limited and come largely from small studies.

Further detail

{\displaystyle {\hat {H}}={\frac {{\hat {p}}_{x}^{2}+{\hat {p}}_{y}^{2}+{\hat {p}}_{z}^{2}}{2m}}+{\frac {\omega _{c}}{2}}({\hat {x}}{\hat {p}}_{y}-{\hat {y}}{\hat {p}}_{x})+{\frac {1}{2}}m\left({\frac {\omega _{1}}{2}}\right)^{2}({\hat {x}}^{2}+{\hat {y}}^{2})+{\frac {1}{2}}m\omega _{z}^{2}{\hat {z}}^{2}}

== Side effects == Chlorprothixene has a strong sedative activity with a high incidence of anticholinergic side effects. The types of side effects encountered (dry mouth, massive hypotension and tachycardia, hyperhidrosis, substantial weight gain etc.) normally do not allow a full effective dose for the remission of psychotic disorders to be given. So cotreatment with another, more potent, antipsychotic agent is needed. Chlorprothixene is structurally related to chlorpromazine, with which it shares, in principle, all side effects. Allergic side effects and liver damage seem to appear with an appreciable lower frequency. The elderly are particularly sensitive to anticholinergic side effects of chlorprothixene (precipitation of narrow angle glaucoma, severe obstipation, difficulties in urinating, confusional and delirant states). In patients >60 years the doses should be particularly low. Early and late extrapyramidal side effects may occur but have been noted with a low frequency (one study with a great number of participants has delivered a total number of only 1%).

== Production == The major producers of strontium as celestine as of January 2024 are Spain (200,000 t), Iran (200,000 t), China (80,000 t), Mexico (35,000 t); and Argentina (700 t). Although strontium deposits occur widely in the United States, they have not been mined since 1959. A large proportion of mined celestine is converted to the carbonate by two processes. Either the celestine is directly leached with sodium carbonate solution or the celestine is roasted with coal to form the sulfide. The second stage produces a dark-coloured material containing mostly strontium sulfide. This so-called "black ash" is dissolved in water and filtered. Strontium carbonate is precipitated from the strontium sulfide solution by introduction of carbon dioxide. The sulfate is reduced to the sulfide by the carbothermic reduction:

TGI Fridays Franchisor, LLC, doing business as TGI Fridays, is an American casual dining restaurant chain focusing primarily on American cuisine. The restaurant's name stands for "Thank God It's Friday". TGI Fridays operates more than 380 locations in more than 35 countries, including 69 in the United States. The chain filed for bankruptcy in the United States on November 2, 2024.

Froud, Kristina E.; Wardhaugh, Tina; Banks, Duncan; Saffrey, M. Jill; Stewart, Michael G. (2010). "Colostrinin™ Alleviates Amyloid-β Induced Toxicity in Rat Primary Hippocampal Cultures" (PDF). Journal of Alzheimer's Disease. 20 (2): 423–426. doi:10.3233/JAD-2010-1382. PMID 20164569.

Sources: en.wikipedia.org

Supporting material

Atomic theory is the scientific theory that matter is composed of particles called atoms. The definition of the word "atom" has changed over the years in response to scientific discoveries. Initially, it referred to a hypothetical fundamental particle of matter, too small to be seen by the naked eye, that could not be divided. Then the definition was refined to being the basic particles of the chemical elements, when chemists observed that elements seemed to combine with each other in ratios of small whole numbers. Then physicists discovered that these atoms had an internal structure of their own and therefore could be divided after all. Atomic theory is one of the most important scientific developments in history, crucial to all the physical sciences. At the start of The Feynman Lectures on Physics, physicist and Nobel laureate Richard Feynman offers the atomic hypothesis as the single most prolific scientific concept.

==== Other uses in biology, medicine, and chemistry ==== Abdominal aortic aneurysm Acral acanthotic anomaly In the initialism OPQRST-AAA, aggravating/alleviating factors, associated symptoms, and attributions/adaptations Cavaticovelia aaa (aaa water treader), an insect from Hawaii, named after ʻaʻaʻā, the Hawaiian word for "lava tube" List of banana cultivars § AAA Group, triploid Musa acuminata

=== Familia Neo/323C/323 Neo === The Familia Neo started production for the Japanese domestic market in 1994 (axed in 1996), and was also sold as the 323C in Europe and the 323 in Canada. Ford released a rebadged version which was mechanically the same although different bumpers, headlights and bonnet were fitted, badged as the Ford Laser Lynx in Japan and Australia, and the Ford Aztec in Taiwan. This model was only available as the Ford Laser Lynx in the Australian market, as Mazda already had the 323 Astina Hatch filling the gap for a hatchback in the Mazda range. To contradict this, Mazda Australia also offered two 323 saloons, the Astina/Lantis hardtop and the 323 Protegé until production of both models ceased in 1998. It featured a rear hatch with a divided glass, much like the Honda CR-X. Aesthetically the Familia Neo was very close in looks to a Mazda Lantis/323F and equated to a three-door version and also shared the Lantis suspension. The top specced Familia Neo was fitted with a DOHC 1839 cc BP-ZE engine which produced around 114–135 PS (84–99 kW) (depending on the market), and this was the same engine fitted to the base model Mazda Lantis. It was also sold for a single year (1995) in Canada as 323 GS. In Europe it was named Mazda 323C (for coupé), available for sale until September 1998 and it was equipped with 1.3 L SOHC, 1.5 L DOHC 16V, and 1.8 L DOHC 16V engine.

== Awards and recognition == 1997: Newcomb Cleveland Prize 1998: W. Alden Spencer Award 1999: Albert Lasker Basic Medical Research Award 2000: Rosenstiel Award 2001: Gairdner Foundation International Award 2003: Louisa Gross Horwitz Prize 2003: Nobel Prize in Chemistry

Sources: en.wikipedia.org

Supporting material

== History and mechanism == As of 2001, 645 unique radical SAM enzymes have been identified from 126 species in all three domains of life. According to the EFI and SFLD databases, more than 220,000 radical SAM enzymes are predicted to be involved in 85 types of biochemical transformations. The mechanism for these reactions entail transfer of a methyl or adenosyl group from sulfur to iron. The resulting organoiron complex subsequently releases the organic radical. The latter step is reminiscent of the behavior of adenosyl and methyl cobalamins.

== Bridging Methods == Integrating traditional and modern methods is a useful way to process albumin. There are three main steps that combine Cohn fractionation with chromatography: 1) factors I, II, and III are removed via cold ethanol fractionation, 2) Sepharose fast flow ion exchange and sepharose fast flow chromatography procedures are run, and 3) gel filtration is run. The result is albumin with 9% lower aluminum levels with a processing time that is almost twice as fast. Although it was hard to make chromatographic processing methods widely adopted, global expansion is a work in progress. Various blood components must be readily available at various medical treatment centers around the world. The Institute of Transfusion Medicine in Skopje, North Macedonia is a plasma fractionation center in the Balkans. Their modernized albumin purification process consists of five steps:

Dithiocarbamate fungicides are also associated with increased PD risk. Organochlorine pesticides such as DDT were banned in the United States in 1972; pesticides such as dieldrin are also associated with increased PD risk and still may be used elsewhere. Organophosphates such as chlorpyrifos and diazinon are linked with increased PD risk, and have been banned in the European Union. Concerns have been raised about pyrethroid pesticides such as cypermethrin, which are globally used both agriculturally and domestically, often as a replacement for organophosphates. Rural living, well-drinking, and farming are all associated with Parkinson's, which may be partly explained by local pesticide exposure through direct contact and contaminated air or ground water. These factors are pertinent to many communities, including Brazilian and South Asian populations. Organochlorine pesticides continue to be associated with increased risk for Parkinson's disease in Asia. In France, Parkinson's disease was officially recognized as an occupational disease of agricultural workers in 2012. A Decree acknowledging a causal link between pesticides and PD entered into force on 7 May 2013. In March 2024, Germany formally adopted a similar recommendation for the occupational disease category of "Parkinson's Disease caused by pesticides", no longer using the term "idiopathic" PD. Since 2019, the Movement Disorder Society (MDS) has included "regular pesticide exposure" as a risk factor in the MDS research criteria for prodromal Parkinson's disease. Many pesticides are mitochondrial toxins.

As of 2008, the United States is the leader in medical research, including pharmaceutical development. U.S. drug prices are among the highest in the world, and drug innovation is correspondingly high. In 2000, U.S.-based firms developed 29 of the 75 top-selling drugs; firms from the second-largest market, Japan, developed eight, and the United Kingdom contributed 10. France, which imposes price controls, developed three. Throughout the 1990s, outcomes were similar.

Polystyrene is commonly injection molded, vacuum formed, or extruded, while expanded polystyrene is either extruded or molded in a special process. Polystyrene copolymers are also produced; these contain one or more other monomers in addition to styrene. Expanded polystyrene composites with cellulose and starch have also been produced. Polystyrene is used in some polymer-bonded explosives (PBX).

Sources: en.wikipedia.org

Frequently asked questions

How does ipamorelin relate to ghrelin?

Both molecules activate the same receptor, GHSR-1a, but they share little sequence identity. Ghrelin is a 28-amino-acid hormone carrying a distinctive acyl modification, whereas ipamorelin is a short synthetic peptide. The shared target explains overlapping endocrine effects, while the different structures account for differences in metabolic stability and receptor selectivity.

Why is it described as selective?

Early animal and human studies reported growth hormone release at levels that produced small changes in cortisol, prolactin and adrenocorticotropic hormone. That contrast with older secretagogues gave rise to the selectivity label. The observation is consistent across several reports but rests on a limited number of small studies.

What is known about its metabolism?

Plasma peptidases cleave the molecule into smaller fragments, and reported half-lives in human studies are on the order of a couple of hours. The identity and activity of individual breakdown products have not been fully mapped. Questions about tissue-level clearance remain open.

What receptor does ipamorelin act on?

It acts on the growth hormone secretagogue receptor, GHS-R1a, which is also the receptor for ghrelin. Binding triggers intracellular signaling that promotes growth hormone release from the pituitary. The interaction is the basis for its classification as a secretagogue.

Network